Showing 3,141 - 3,160 results of 4,404 for search '"clinical trials"', query time: 0.11s Refine Results
  1. 3141

    Pharmacological action of Angelica sinensis polysaccharides: a review by Chunzhen Ren, Chunzhen Ren, Chunzhen Ren, Yali Luo, Xiaojuan Li, Like Ma, Chunling Wang, Chunling Wang, Chunling Wang, Xiaodong Zhi, Xiaodong Zhi, Xinke Zhao, Xinke Zhao, Xinke Zhao, Yingdong Li, Yingdong Li, Yingdong Li

    Published 2025-01-01
    “…However, further research should be undertaken to clarify the unconfirmed regulatory mechanisms, conduct standard clinical trials, and evaluate the possible side effects. …”
    Get full text
    Article
  2. 3142

    Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma by Wei Gao, Tong Ding, Beicheng Sun, Nan Li, Fang Gao, Meng Jia, Mitchell Ho, Na Li, Luan Sun, Zhanhui Gao, Lei Ao, Sujuan Ma, Peihua Lu, Shaochang Jia

    Published 2021-04-01
    “…Therefore, sGPC3 acted as dominant negative regulators when competed with cell surface GPC3 to bind anti-GPC3 CAR-T cells, leading to an inhibitory effect on CAR-T cells in HCC.Conclusions We provide a proof-of-concept study demonstrating that GPC3 shedding might cause worse response to CAR-T cell treatment by competing with cell surface GPC3 for CAR-T cell binding, which revealed a new mechanism of tumor immune escape in HCC, providing a novel biomarker for patient enrolment in future clinical trials and/or treatments with GPC3-targeted CAR-T cells.…”
    Get full text
    Article
  3. 3143
  4. 3144
  5. 3145
  6. 3146

    Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults by Florence Ader, Jean-François Timsit, Yazdan Yazdanpanah, François-Xavier Lescure, Laetitia Moinot, Christelle Delmas, Hélène Espérou, Laurent Abel, Benjamin Leveau, Vinca Icard, Toni Alfaiate, Linda Wittkop, Charles Burdet, France Mentré, Marion Schneider, Nathan Peiffer-Smadja, Julien Poissy, Lila Bouadma, Bruno Lina, Florence Morfin-Sherpa, Maude Bouscambert, Alexandre Gaymard, Gilles Peytavin, Jeremie Guedj, Claire Andrejak, Cedric Laouenan, Drifa Belhadi, Axelle Dupont, Basma Basli, Anissa Chair, Samira Laribi, Julie Level, Marie-Capucine Tellier, Aline Dechanet, Dominique Costagliola, Sandrine Couffin-Cadiergues, Juliette Saillard, Claire Fougerou, Carole Cagnot, Soizic Le Mestre, Delphine Lebrasseur-Longuet, Ventzislava Petrov-Sanchez, Alpha Diallo, NoéMie Mercier, Sarah Tubiana, Benjamin Hamze, Ambre Gelley, Marion Noret, Eric D’Ortenzio, Oriane Puechal, Caroline Semaille

    Published 2020-09-01
    “…Introduction To find effective and safe treatments for COVID-19, the WHO recommended to systemically evaluate experimental therapeutics in collaborative randomised clinical trials. As COVID-19 was spreading in Europe, the French national institute for Health and Medical Research (Inserm) established a transdisciplinary team to develop a multi-arm randomised controlled trial named DisCoVeRy. …”
    Get full text
    Article
  7. 3147

    Rationale and design of a multicentre randomised controlled trial on circulating tumour DNA-guided neoadjuvant treatment strategy for locally advanced rectal cancer (CINTS-R) by Bin Wu, Yi Xiao, Xiao Zhang, Tao Xu, Qian Liu, Wei Fu, Yang An, Yongheng Li, Guole Lin, Huadan Xue, Guoju Wu, Jiaolin Zhou, Hongwei Yao, Zhenjun Wang, Weijie Chen, Junyang Lu, Guannan Zhang, Xiaoyuan Qiu

    Published 2025-02-01
    “…The results of our trial will be disseminated through peer-reviewed publications and presented at national and international academic conferences.Trial registration number This trial is registered on ClinicalTrials.gov and the registration ID is NCT05601505.…”
    Get full text
    Article
  8. 3148

    Real-world outcomes of the CROSS regimen in patients with resectable esophageal or gastro-esophageal junction adenocarcinoma: a nationwide cohort study in the NetherlandsResearch i... by Hanneke van Laarhoven, Rob Verhoeven, Mark van Berge Henegouwen, Nadia Haj Mohammad, Richard van Hillegersberg, Marije Slingerland, Christina T. Muijs, Bas Wijnhoven, Bianca Mostert, Laurens Beerepoot, Grard Nieuwenhuijzen, Sarah Derks, Peter S.N. van Rossum

    Published 2025-02-01
    “…Interpretation: Although survival rates in real-world settings are often lower compared to clinical trials, in our real-world cohort the 3-year OS was only 2.6% lower compared to that reported for the group that underwent nCRT in ESOPEC. …”
    Get full text
    Article
  9. 3149
  10. 3150

    Recruitment of Young Gay, Bisexual, and Other Men Who Have Sex With Men for a Web-Based Human Papillomavirus Vaccination Intervention: Differences in Participant Characteristics an... by Daniel J Marshall, Amy L Gower, Mira L Katz, José A Bauermeister, Abigail B Shoben, Paul L Reiter

    Published 2025-01-01
    “…Trial RegistrationClinicalTrials.gov NCT04032106; https://clinicaltrials.gov/study/NCT04032106 International Registered Report Identifier (IRRID)RR2-10.2196/16294…”
    Get full text
    Article
  11. 3151
  12. 3152
  13. 3153
  14. 3154

    New avenues of preoperative evaluation before corneal refractive surgery during the COVID-19 pandemic by S.N. Sakhnov, O.A. Klokova, A.V. Piskunov, R.O. Damashauskas, M.S. Geidenrich, E.I. Dyakonova

    Published 2021-05-01
    “…</i> </p> <p> <i><b>Conclusion</b>: clinical trials comparing the readings produced by Visionix VX 130+ and other devices whose reliability was evidenced by long-term clinical experience have demonstrated that Visionix VX 130+ multifunctional diagnostic system is fully in line with the COVID-19 pandemic requirements. …”
    Get full text
    Article
  15. 3155
  16. 3156
  17. 3157
  18. 3158

    A cohort-based multi-omics identifies nuclear translocation of eIF5B /PD-L1/CD44 complex as the target to overcome Osimertinib resistance of ARID1A-deficient lung adenocarcinoma by Dantong Sun, Helei Hou, Feiyue Feng, Weizheng Wu, Jingyu Tan, Tongji Xie, Jiayu Liu, Jinsong Wang, Haili Qian, Junling Li, Puyuan Xing

    Published 2025-01-01
    “…Abstract Background Osimertinib has emerged as a critical element in the treatment landscape following recent clinical trials. Further investigation into the mechanisms driving resistance to Osimertinib is necessary to address the restricted treatment options and survival advantages that are compromised by resistance in patients with EGFR-mutated lung adenocarcinoma (LUAD). …”
    Get full text
    Article
  19. 3159
  20. 3160